Compare HTO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTO | NUVB |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | 837 | 307 |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | HTO | NUVB |
|---|---|---|
| Price | $66.84 | $6.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $62.00 | $11.38 |
| AVG Volume (30 Days) | 477.0K | ★ 7.1M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | $203.82 |
| Revenue Next Year | $7.06 | $58.18 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.75 | $2.18 |
| 52 Week High | $66.05 | $9.75 |
| Indicator | HTO | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 60.56 |
| Support Level | $55.76 | $5.28 |
| Resistance Level | N/A | $6.60 |
| Average True Range (ATR) | 1.34 | 0.37 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 88.70 | 75.16 |
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.